Mild cognitive impairment

Expert Review of Neurotherapeutics

Volumn 13, Issue 11, 2013, Pages 1247-1261

  Gordon, Craig ^a   Martin, Daniel J ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Alzheimers; Dementia; Early identification; Mental health; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; COPPER; FLUORODEOXYGLUCOSE F 18; HEME; HEMOGLOBIN A1C; IRON;

AGING; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; AMYLOID PLAQUE; AWARENESS; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CLINICAL DEMENTIA RATING; CLINICAL FEATURE; COGNITION; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DIAGNOSTIC ACCURACY; EDUCATION; ELECTROENCEPHALOGRAM; EPISODIC MEMORY; ETHNICITY; EXECUTIVE FUNCTION; EXERCISE; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INTELLIGENCE; ISCHEMIC HEART DISEASE; LEWY BODY; LUNG FUNCTION; MEDITERRANEAN DIET; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); MULTIINFARCT DEMENTIA; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATIENT EDUCATION; POSITRON EMISSION TOMOGRAPHY; PSYCHOMETRY; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REM SLEEP; RESISTANCE TRAINING; REVIEW; RISK FACTOR; SCREENING TEST; SEMANTIC MEMORY; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TRAUMATIC BRAIN INJURY;

DEMENTIA; HUMANS; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887308585     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.856265     Document Type: Review

References (132)

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56(3), 303-308 (1999).
2. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch. Neurol. 62(7), 1160-1163, discussion 1167 (2005).
3. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 256(3), 240-246 (2004).
4. Kral VA. Senescent forgetfulness: benign and malignant. Can. Med. Assoc. J. 86, 257-260 (1962).
5. O'Brien J. Age-associated memory impairment and related disorders. Adv. Psychiatric Treat. 5(4), 279-287 (1999).
6. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 355(9199), 225-228 (2000).
7. Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J. Alzheimers Dis. 12(1), 23-35 (2007).
8. Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256(3), 183-194 (2004).
9. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 270-279 (2011).
10. Morris JC. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch. Neurol. 69(6), 700-708 (2012).
11. Petersen RC. Clinical practice. Mild cognitive impairment. N. Engl. J. Med. 364(23), 2227-2234 (2011).
12. Perneczky R, Pohl C, Sorg C, et al. Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age Ageing. 35(3), 240-245 (2006).
13. Jessen F, Wolfsgruber S, Wiese B et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement. doi:10.1016/j. jalz.2012.09.017 (2013) (Epub ahead of print).
14. Weiner MW, Veitch DP, Aisen PS et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 8(SUPPL. 1), S1-S68 (2012).
15. Jessen F, Wiese B, Bachmann C et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch. Gen. Psychiatry. 67(4), 414-422 (2010).
16. Mitchell AJ. The clinical significance of subjective memory complaints in the diagnosis of mild cognitive impairment and dementia: a meta-analysis. Int. J. Geriatr. Psychiatry. 23(11), 1191-1202 (2008).
17. Loewenstein DA, Greig MT, Schinka JA et al. An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers Dement. 8(3), 172-179 (2012).
18. O'Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurol. 2(2), 89-98 (2003).
19. Plassman BL, Langa KM, Fisher GG et al. Prevalence of cognitive impairment without dementia in the United States. Ann. Intern. Med. 148(6), 427-434 (2008).
20. Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 7(3), 246-255 (2008).
21. Hachinski V, Iadecola C, Petersen RC et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37(9), 2220-2241 (2006).
22. Hughes TF, Snitz BE, Ganguli M. Should mild cognitive impairment be subtyped? Curr. Opin. Psychiatry. 24(3), 237-242 (2011).
23. He J, Farias S, Martinez O, Reed B, Mungas D, Decarli C. Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch. Neurol. 66(11), 1393-1399 (2009).
24. Nordlund A, Rolstad S, Klang O, Edman A , Hansen S, Wallin A . Two-year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J. Neurol. Neurosurgery. Psychiatry. 81(5), 541-546 (2010).
25. Molano J, Boeve B, Ferman T et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain. (Pt. 2), 133, 540-556 (2010).
26. Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat. Disord. 16(3), 177-180 (2010).
27. Duff K, Paulsen J, Mills J et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 75(6), 500-507 (2010).
28. Lopez OL, Jagust WJ, DeKosky ST et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch. Neurol. 60(10), 1385-1389 (2003).
29. Graham JE, Rockwood K, Beattie BL et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 349(9068), 1793-1796 (1997).
30. Das SK, Bose P, Biswas A et al. An epidemiologic study of mild cognitive impairment in Kolkata, India. Neurology. 68(23), 2019-2026 (2007).
31. Sosa AL, Albanese E, Stephan BC et al. Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study. PLoS Med. 9(2), e1001170 (2012).
32. Larrieu S, Letenneur L, Orgogozo JM et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59(10), 1594-1599 (2002).
33. Luck T, Luppa M, Briel S, Riedel-Heller SG. Incidence of mild cognitive impairment: a systematic review. Dement Geriatr. Cogn. Disord. 29(2), 164-175 (2010).
34. Roberts RO, Geda YE, Knopman DS et al. The incidence of MCI differs by subtype and is higher in men: the Mayo clinic study of aging. Neurology. 78(5), 342-351 (2012).
35. Lopez OL, Becker JT, Chang YF et al. Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 79(15), 1599-1606 (2012).
36. Ward A, Arrighi HM, Michels S, Cedarbaum JM. Mild cognitive impairment: disparity of incidence and prevalence estimates. Alzheimers Dement. 8(1), 14-21 (2012).
37. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta. Psychiatr. Scand. 119(4), 252-265 (2009).
38. Jak AJ, Bondi MW, Delano-Wood L et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am. J. Geriatr. Psychiatry. 17(5), 368-375 (2009).
39. Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 79(15), 1591-1598 (2012).
40. Caselli RJ, Dueck AC, Osborne D et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med. 361(3), 255-263 (2009).
41. Mosconi L, De Santi S, Brys M et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol. Psychiatry 63(6), 609-618 (2008).
42. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian study of health and aging. CMAJ 171(8), 863-867 (2004).
43. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology 66(6), 828-832 (2006).
44. Risacher SL, Kim S, Shen L et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front. Aging Neurosci. 5, 11 (2013).
45. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch. Neurol. 64(12), 1734-1740 (2007).
46. Wysocki M, Luo X, Schmeidler J, Dahlman K, Lesser GT, Grossman H et al. Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am. J. Geriatr. Psychiatry 20(2), 179-187 (2012).
47. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch. Neurol. 64(4), 570-575 (2007).
48. Yaffe K, Falvey C, Hamilton N et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch. Neurol. 69(9), 1170-1175 (2012).
49. Xu W, Caracciolo B, Wang HX et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 59(11), 2928-2935 (2010).
50. Roberts RO, Geda YE, Knopman DS et al. Cardiac disease associated with increased risk of nonamnestic cognitive impairment: stronger effect on women. JAMA Neurol. 70(3), 374-382 (2013).
51. Solfrizzi V, Scafato E, Capurso C et al. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging. Neurobiol. Aging 32(11), 1932-1941 (2011).
52. Vidal JS, Aspelund T, Jonsdottir MK et al. Pulmonary function impairment may be an early risk factor for late-life cognitive impairment. J. Am. Geriatr. Soc. 61(1), 79-83 (2013).
53. Solfrizzi V, Colacicco AM, D'Introno A et al. Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian longitudinal study on aging. Neurobiol. Aging 27(11), 1694-1704 (2006).
54. Cherbuin N, Anstey KJ. The Mediterranean diet is not related to cognitive change in a large prospective investigation: the PATH through life study. Am. J. Geriatr. Psychiatry 20(7), 635-639 (2012).
55. Peters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 37(5), 505-512 (2008).
56. Roberts RO, Geda YE, Cerhan JR et al. Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 29(5), 413-423 (2010).
57. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332(7539), 455-459 (2006).
58. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 29(8), 639-658 (2012).
59. Gao Y, Huang C, Zhao K et al. Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Int. J. Geriatr. Psychiatry 28(5), 441-449 (2013).
60. Richard E, Reitz C, Honig LH et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol. 70(3), 374-382 (2013).
61. Geda YE, Roberts RO, Knopman DS et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch. Neurol. 67(1), 80-86 (2010).
62. Barber SE, Clegg AP, Young JB. Is there a role for physical activity in preventing cognitive decline in people with mild cognitive impairment? Age Ageing 41(1), 5-8 (2012).
63. Dufouil C, Alperovitch A, Tzourio C. Influence of education on the relationship between white matter lesions and cognition. Neurology. 60(5), 831-836 (2003).
64. Mueller C, Schrag M, Crofton A et al. Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment. J. Alzheimers Dis. 29(2), 341-350 (2012).
65. Mauri M, Sinforiani E, Bono G et al. Interaction between Apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's disease and Mild Cognitive Impairment. Funct. Neurol. 21(4), 223-228 (2006).
66. Moretti L, Cristofori I, Weaver SM, Chau A, Portelli JN, Grafman J. Cognitive decline in older adults with a history of traumatic brain injury. Lancet Neurol. 11(12), 1103-1112 (2012).
67. Fischer P, Jungwirth S, Zehetmayer S et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology 68(4), 288-291 (2007).
68. Gainotti G. Origins, controversies and recent developments of the MCI construct. Curr. Alzheimer Res. 7(3), 271-279 (2010).
69. Apostolova LG, Dutton RA, Dinov ID et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch. Neurol. 63(5), 693-699 (2006).
70. Jack CR Jr, Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52(7), 1397-1403 (1999).
71. Jack CR Jr, Lowe VJ, Senjem ML et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, (Pt. 3), 665-680 (2008).
72. Jack CR Jr, Wiste HJ, Vemuri P et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133(11), 3336-3348 (2010).
73. Devanand DP, Bansal R, Liu J, Hao X, Pradhaban G, Peterson BS. MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease. Neuroimage 60(3), 1622-1629 (2012).
74. Spulber G, Simmons A, Muehlboeck JS et al. An MRI-based index to measure the severity of Alzheimer's disease-like structural pattern in subjects with mild cognitive impairment. J. Intern. Med. 273(4), 396-409 (2013).
75. Jack CR Jr, Barkhof F, Bernstein MA et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 7(4), 474-485.e4 (2011).
76. Driscoll I, Davatzikos C, An Y et al. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 72(22), 1906-1913 (2009).
77. Kantarci K, Weigand SD, Przybelski SA et al. MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology 81(2), 126-133 (2013).
78. Leung KK, Bartlett JW, Barnes J et al. Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. Neurology. 80(7), 648-654 (2013).
79. Bozzali M, Filippi M, Magnani G et al. The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology 67(3), 453-460 (2006).
80. Risacher SL, Saykin AJ, West JD et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr. Alzheimer Res. 6(4), 347-361 (2009).
81. Moretti DV, Frisoni GB, Fracassi C et al. MCI patients' EEGs show group differences between those who progress and those who do not progress to AD. Neurobiol. Aging 32(4), 563-571 (2011).
82. Drago V, Babiloni C, Bartres-Faz D et al. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J. Alzheimers Dis. 26, (SUPPL. 3), 159-199 (2011).
83. Nardone R, Bergmann J, Christova M et al. Short latency afferent inhibition differs among the subtypes of mild cognitive impairment. J. Neural. Transm. 119(4), 463-471 (2012).
84. Jack CRJr, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9(1), 119-128 (2010).
85. Biagioni MC, Galvin JE. Using biomarkers to improve detection of Alzheimer's disease. Neurodegener. Dis. Manag. 1(2), 127-139 (2011).
86. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Neurol. 55(3), 306-319 (2004).
87. Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66(12), 1469-1475 (2009).
88. Okello A, Koivunen J, Edison P et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73(10), 754-760 (2009).
89. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int. J. Clin. Pract. 66(2), 185-198 (2012).
90. Petersen RC, Parisi JE, Dickson DW et al. Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 63(5), 665-672 (2006).
91. Small GW, Kepe V, Ercoli LM et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355(25), 2652-2663 (2006).
92. Small GW, Siddarth P, Kepe V et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch. Neurol. 69(2), 215-222 (2012).
93. Wu L, Rowley J, Mohades S et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS ONE 7(10), e47905 (2012).
94. Mosconi L, Perani D, Sorbi S et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63(12), 2332-2340 (2004).
95. Jokinen H, Lipsanen J, Schmidt R et al. Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. Neurology 78(22), 1785-1792 (2012).
96. LADIS Study Group. 2001-2011: a decade of the LADIS (Leukoaraiosis And DISability) Study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc. Dis. 32(6), 577-588 (2011).
97. Eckerstrom C, Olsson E, Klasson N et al. High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 31(2), 132-138 (2011).
98. Devine ME, Fonseca JA, Walker Z. Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia? Int. Psychogeriatr. 25(1), 120-127 (2013).
99. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. 107(3), 165-173 (2005).
100. Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J. Neurol. Neurosurg. Psychiatry 80(9), 966-975 (2009).
101. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of b-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69(1), 98-106 (2012).
102. Prestia A, Caroli A, van der Flier WM et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80(11), 1048-1056 (2013).
103. Vos SJ, van Rossum IA, Verhey F et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology 80(12), 1124-1132 (2013).
104. Visser PJ, Verhey F, Knol DL et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8(7), 619-627 (2009).
105. Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol. Med. 40(1), 135-145 (2010).
106. Richard E, Schmand BA, Eikelenboom P, Van Gool WA. Alzheimer's Disease Neuroimaging Initiative. MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study. BMJ Open 3(6), e002541 (2013).
107. Palmqvist S, Hertze J, Minthon L et al. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. PLoS ONE 7(6), e38639 (2012).
108. Cullen B, O'Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for cognitive impairment. J. Neurol. Neurosurg. Psychiatry 78(8), 790-799 (2007).
109. Ismail Z, Rajji TK, Shulman KI. Brief cognitive screening instruments: an update. Int. J. Geriatr. Psychiatry 25(2), 111-120 (2010).
110. Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int. Psychogeriatr. 12(2), 231-247 (2000).
111. Rodda J, Gandhi SD, Mukadam N, Walker Z. Attitudes of UK psychiatrists to the diagnosis of MCI in clinical practice. Int. Psychogeriatr. 25(2), 286-291 (2013).
112. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12(3), 189-198 (1975).
113. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. J. Psychiatr. Res. 43(4), 411-431 (2009).
114. Diniz BS, Yassuda MS, Nunes PV, Radanovic M, Forlenza OV. Mini-mental State Examination performance in mild cognitive impairment subtypes. Int. Psychogeriatr. 19(4), 647-656 (2007).
115. Law E, Connelly PJ, Randall E et al. Does the Addenbrooke's Cognitive Examination-revised add to the Mini-Mental State Examination in established Alzheimer disease? Results from a national dementia research register. Int. J. Geriatr. Psychiatry 28(4), 351-355 (2013).
116. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int. J. Geriatr. Psychiatry 21(11), 1078-1085 (2006).
117. Lonie JA, Parra-Rodriguez MA, Tierney KM et al. Predicting outcome in mild cognitive impairment: 4-year follow-up study. Br. J. Psychiatry. 2004 197(2), 135-140 (2004).
118. Kalbe E, Kessler J, Calabrese P et al. DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int. J. Geriatr. Psychiatry 19(2), 136-143 (2004).
119. Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53(4), 695-699 (2005).
120. Smith T, Gildeh N, Holmes C. The Montreal cognitive assessment: validity and utility in a memory clinic setting. Can. J. Psychiatry. 52(5), 329-332 (2007).
121. Galvin JE, Roe CM, Powlishta KK et al. The AD8: a brief informant interview to detect dementia. Neurology 65(4), 559-564 (2005).
122. Sarazin M, Berr C, De Rotrou J et al. Amnestic syndrome of the medial temporal type identifies prodromal AD A longitudinal study. Neurology 69(19), 1859-1867 (2007).
123. Perri R, Serra L, Carlesimo GA, Caltagirone C. Amnestic mild cognitive impairment: Difference of memory profile in subjects who converted or did not convert to Alzheimer's disease. Neuropsychology 21(5), 549 (2007).
124. Royall DR, Chiodo LK, Polk MJ. Misclassification is likely in the assessment of mild cognitive impairment. Neuroepidemiology 23(4), 185-191 (2004).
125. Levey A, Lah J, Goldstein F, Steenland K, Bliwise D. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin. Ther. 28(7), 991-1001 (2006).
126. O'Brien JT, Burns A. BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J. Psychopharmacol. 25(8), 997-1019 (2011).
127. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst. Rev. 9, CD009132 (2012).
128. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev. (4), CD004034 (2009).
129. Nagamatsu LS, Handy TC, Hsu CL, Voss M, Liu-Ambrose T. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch. Intern. Med. 172(8), 666-668 (2012).
130. Hahn EA, Andel R. Nonpharmacological therapies for behavioral and cognitive symptoms of mild cognitive impairment. J. Aging Health 23(8), 1223-1245 (2011).
131. National Institute for Health and Care Excellence. Dementia-supporting people with dementia and their carers in health and social care (CG42). SCIE (2006).
132. Duara R, Loewenstein DA, Greig MT et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am. J. Geriatr. Psychiatry 19(11), 951-960 (2011).